ME00519B - Antitijela visokog afiniteta prema humanom il-6 receptoru - Google Patents
Antitijela visokog afiniteta prema humanom il-6 receptoruInfo
- Publication number
- ME00519B ME00519B MEP-2008-853A MEP85308A ME00519B ME 00519 B ME00519 B ME 00519B ME P85308 A MEP85308 A ME P85308A ME 00519 B ME00519 B ME 00519B
- Authority
- ME
- Montenegro
- Prior art keywords
- seq
- antibody
- binding fragment
- antigen
- heavy chain
- Prior art date
Links
- 102000010781 Interleukin-6 Receptors Human genes 0.000 title 1
- 108010038501 Interleukin-6 Receptors Proteins 0.000 title 1
- 239000012634 fragment Substances 0.000 claims abstract 20
- 239000000427 antigen Substances 0.000 claims abstract 17
- 102000036639 antigens Human genes 0.000 claims abstract 17
- 108091007433 antigens Proteins 0.000 claims abstract 17
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims abstract 2
- 102000052611 human IL6 Human genes 0.000 claims abstract 2
- 102000005962 receptors Human genes 0.000 claims abstract 2
- 108020003175 receptors Proteins 0.000 claims abstract 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 102000004889 Interleukin-6 Human genes 0.000 claims 4
- 108090001005 Interleukin-6 Proteins 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 241000282412 Homo Species 0.000 claims 3
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 102000052623 human IL6R Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 241000588724 Escherichia coli Species 0.000 claims 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000003527 eukaryotic cell Anatomy 0.000 claims 1
- 108040006858 interleukin-6 receptor activity proteins Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 210000001236 prokaryotic cell Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
Claims (19)
1. Antitelo ili njegov antigen-vezujući fragment, koji se specifično vezuje za humani interleukin-6 receptor (hIL-6R) sa KD od otprilike 500 pM i manjom i, 300 pM i manjom, mereno površinskom plazmon rezonancom.
2. Antitelo ili njegov antigen-vezujući fragment, kao u patentnom zahtevu 1, koje vezuje hIL-6R sa afinitetom od najmanje 2-puta većim u odnosu na njegovo vezivanje za majmunski IL-6R.
3. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koji sadrže domen komplementarnog determinišućeg regiona 3 (CDR3)teškog lanca i CDR3 domen lakog lanca, gde: teški lanac CDR3 domena obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X1-X8-X9-X10-X11-X12-X13-X14-X15-X16-X11-X18-X19 (SEQ ID NO: 247) u kojoj je: X1=Ala, X2=Lys, X3=Gly, X4=Arg, X1=Asp, X2=Ser ili Ala, X7=Phe, X8=Asp, X9=Ile, X10=Pro ili ga nema, X11=Phe ili ga nema, X12=Val ili ga nema, X13=Tyr ili ga nema, Xl4=Tyr ili ga nema, X15=Tyr ili ga nema, Xl6=Gly ili ga nema, X17 =Met ili ga nema, X18=Asp ili ga nema i, X19=Val ili ga nema; i laki lanac CDR3 domena obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X7-X8-X9(SEQ ID NO: 250) u kojoj je: X1=Gln, X2=Gln ili His, X3=Ala, X4=Asn ili Tyr, X1=Ser, X2=Phe, X7=Pro, X2=Pro i, X9=Thr.
4. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 3, koji dalje sadrže teški lanac CDR1 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO: 245) u kojoj je: X1=Gly ili Arg, X2=Phe, X3=Thr, X4=Phe, X1=Asp, X2=Asp, X7=Tyr i, X8=Ala; teški lanac CDR2 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X1-X2-X7-X8 (SEQ ID NO: 246) u kojoj je: X1=Ile ili Val, X2=Ser, X3=Trp, X4=Asn, X1=Ser, X2=Gly, X7=Ser i, X8=Ile; laki lanac CDR1 domena, koji obuhvata amino kiselinsku sekvencu formule: X1-X2-X3-X4-X5-X6-X7-X8 (SEQ ID NO: 248) u kojoj je: X1=Gln, X2=Gly, X3=Ile, X4=Ser, X1=Ser i, X6=Trp; i laki lanac CDR2 domena, koji obuhvata amino kiselinsku sekvencu formule: X3-X2-X3 (SEQ ID NO: 249) u kojoj je: X1=Gly ili Ala, X2=Ala i, X3=Ser.
5. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koji sadrže: teški lanac CDR3 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 25, 153, 9, 185, 41, 57, 73, 89, 105, 121, 137, 169, 201 i 217; i laki lanac CDR3 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 33, 161, 17, 193, 49, 65, 81, 97, 113, 129, 145, 177, 209 i 225.
6. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 5, koji dalje sadrže: teški lanac CDR1 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 21, 149, 5, 181, 37, 53, 69, 85, 101, 117, 133, 165, 197 i 213; teški lanac CDR2 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 23, 151, 7, 183, 39, 55, 71, 87, 103, 119, 135, 167, 199 i 215; laki lanac CDR1 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 29, 157, 13, 189, 45, 61, 77, 93, 109, 125, 141, 173, 205 i 221; i laki lanac CDR2 domena koji je odabran iz grupe, koja se sastoji od SEQ ID NO: 31, 159, 15, 191, 47, 63, 79, 95, 111, 127, 143, 175, 207 i 223.
7. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 5 ili 6, gde CDR teškog lanca i CDR lakog lanca sadrže: SEQ ID NO: 21, 23, 25 i SEQ ID NO: 29, 31, 33; SEQ ID NO: 149, 151, 153 i SEQ ID NO: 157, 159, 161; SEQ ID NO: 5, 7, 9 i SEQ ID NO: 13, 15, 17; i SEQ ID NO: 181, 183, 185 i SEQ ID NO: 189, 191, odnosno 193.
8. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 1 ili 2, koje sadrži varijabilni region teškog lanca (HCVR), odabran iz grupe, koja se sastoji od SEQ ID NO: 19, 147, 3, 179, 227, 231, 35, 51, 67, 83, 99, 115, 131, 239, 241, 163, 235, 195 i 211; i promenljivi region lakog lanca (LCVR), odabran iz grupe, koja se sastoji od SEQ ID NO: 27, 155, 11, 187, 229, 233, 43, 59, 75, 91, 107, 123, 139, 171, 237, 203 i 219.
9. Antitelo ili antigen vezujući fragment, kao u patentnom zahtevu 8, koje sadrži HCVR/LCVR parove, odabrane iz grupe, koja se sastoji od SEQ ID NO: 19/27; 147/155; 3/11; 179/187; 227/229; 231/233; 35/43; 51/59; 67/75; 83/91; 99/107; 115/123; 131/139; 239/155; 241/155; 163/171; 235/237; 195/203 i 211/219.
10. Izolovani molekul nukleinske kiseline koji kodira antitelo ili antigen vezujući fragment, kao u bilo kom od prethodnih patentnih zahteva.
11. Vektor, koji obuhvata nukleotidnu sekvencu, kao u patentnom zahtevu 10.
12. Sistem domaćin-vektor za proizvodnju antitela ili antigen vezujućeg fragmenta antitela koje specifično vezuje humani IL-6 receptor, koji obuhvata vektor, kao u patentnom zahtevu 11 u pogodnoj ćeliji domaćina.
13. Sistem domaćin-vektor, kao u patentnom zahtevu 12, u kome je ćelija domaćina prokariotska ili eukariotska ćelija odabrana od E. coli ili CHO ćelije.
14. Postupak proizvodnje anti-IL-6R antitela ili njegovog antigen-vezujućeg fragmenta, koji obuhvata uzgajanje ćelija sistema domaćin-vektor, kao u patentnom zahtevu 12 ili 13, u uslovima koji omogućavaju proizvodnju antitela ili njegovog fragmenta i vađenje tako proizvedenog antitela ili njegovog fragmenta.
15. Upotreba antitela ili antigen-vezujućeg fragmenta antitela, kao u bilo kom od patentnih zahteva 1 do 9, u proizvodnji leka za upotrebu za umanjivanje ili inhibiranje bolesti ili poremećaja kod ljudi, posredovanih IL-6.
16. Antitelo ili antigen-vezujući fragment antitela, kao u bilo kom od patentnih zahteva 1 do 9, za upotrebu u umanjivanju ili inhibiciji bolesti ili poremećaja kod ljudi, koji su posredovani IL-6.
17. Farmaceutska smeša koja sadrži antitelo ili antigen-vezujući fragment antitela, kao u bilo kom od patentnih zahteva 1 do 9 i, farmaceutski prihvatljiv nosač ili podlogu.
18. Postupak umanjivanja ili inhibisanja bolesti ili poremećaja kod ljudi, koji su posredovani IL-6, postupak obuhvata primenjivanje pacijentu čoveku, efektivne količine antitela ili antigen-vezujućeg fragmenta antitela, kao u bilo kom od patentnih zahteva 1 do 9.
19. Postupak, kao u patentnom zahtevu 18, u kome je bolest ili poremećaj posredovan IL-6 artritis, kao hronični reumatoidni artritis;
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US81066406P | 2006-06-02 | 2006-06-02 | |
| US84323206P | 2006-09-08 | 2006-09-08 | |
| PCT/US2007/013062 WO2007143168A2 (en) | 2006-06-02 | 2007-06-01 | High affinity antibodies to human il-6 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME00519B true ME00519B (me) | 2011-10-10 |
Family
ID=38792460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2008-853A ME00519B (me) | 2006-06-02 | 2007-06-01 | Antitijela visokog afiniteta prema humanom il-6 receptoru |
Country Status (33)
| Country | Link |
|---|---|
| US (10) | US7582298B2 (me) |
| EP (2) | EP2041177B1 (me) |
| JP (3) | JP5307708B2 (me) |
| KR (1) | KR101464502B1 (me) |
| CN (2) | CN101454345B (me) |
| AT (1) | ATE537190T1 (me) |
| AU (1) | AU2007254831B2 (me) |
| BR (1) | BRPI0712224B8 (me) |
| CA (1) | CA2652976C (me) |
| CR (1) | CR10462A (me) |
| CY (3) | CY1112456T1 (me) |
| DK (2) | DK2041177T3 (me) |
| ES (2) | ES2377579T3 (me) |
| GT (1) | GT200800272A (me) |
| HR (2) | HRP20120175T1 (me) |
| HU (1) | HUS1700050I1 (me) |
| IL (1) | IL195393A (me) |
| LT (1) | LTC2041177I2 (me) |
| LU (1) | LUC00050I2 (me) |
| ME (1) | ME00519B (me) |
| MX (1) | MX2008014804A (me) |
| MY (2) | MY147468A (me) |
| NL (1) | NL300911I2 (me) |
| NO (2) | NO340778B1 (me) |
| NZ (2) | NZ587107A (me) |
| PL (2) | PL2374818T3 (me) |
| PT (2) | PT2041177E (me) |
| RS (2) | RS52176B (me) |
| RU (1) | RU2433138C2 (me) |
| SI (2) | SI2374818T1 (me) |
| SV (1) | SV2008003113A (me) |
| TN (1) | TNSN08502A1 (me) |
| WO (1) | WO2007143168A2 (me) |
Families Citing this family (379)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| AU2003250074B2 (en) | 2002-07-18 | 2010-09-09 | Merus N.V. | Recombinant production of mixtures of antibodies |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395017A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| WO2007046489A1 (ja) | 2005-10-21 | 2007-04-26 | Chugai Seiyaku Kabushiki Kaisha | 心疾患治療剤 |
| CA2647846C (en) | 2006-03-31 | 2016-06-21 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
| US9260516B2 (en) | 2006-04-07 | 2016-02-16 | Osaka University | Method for promoting muscle regeneration by administering an antibody to the IL-6 receptor |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| WO2008065384A2 (en) * | 2006-11-30 | 2008-06-05 | Astrazeneca Ab | Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| MX2009007830A (es) | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
| US8252286B2 (en) | 2007-05-21 | 2012-08-28 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8062864B2 (en) | 2007-05-21 | 2011-11-22 | Alderbio Holdings Llc | Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies |
| US9701747B2 (en) | 2007-05-21 | 2017-07-11 | Alderbio Holdings Llc | Method of improving patient survivability and quality of life by anti-IL-6 antibody administration |
| US8404235B2 (en) | 2007-05-21 | 2013-03-26 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US7906117B2 (en) | 2007-05-21 | 2011-03-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US8178101B2 (en) * | 2007-05-21 | 2012-05-15 | Alderbio Holdings Inc. | Use of anti-IL-6 antibodies having specific binding properties to treat cachexia |
| SI3187506T1 (sl) | 2007-05-21 | 2019-08-30 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| JP5859202B2 (ja) * | 2007-05-21 | 2016-02-10 | アルダーバイオ・ホールディングズ・エルエルシー | 新規のウサギ抗体ヒト化方法及びヒト化ウサギ抗体 |
| US20090238825A1 (en) * | 2007-05-21 | 2009-09-24 | Kovacevich Brian R | Novel rabbit antibody humanization methods and humanized rabbit antibodies |
| US7988967B2 (en) | 2007-08-10 | 2011-08-02 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human nerve growth factor |
| CN106519025B (zh) | 2007-09-26 | 2021-04-23 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| KR102339457B1 (ko) | 2007-09-26 | 2021-12-14 | 추가이 세이야쿠 가부시키가이샤 | 항체 정상영역 개변체 |
| US20110245473A1 (en) | 2007-09-26 | 2011-10-06 | Chugai Seiyaku Kabushiki Kaisha | Anti-IL-6 Receptor Antibody |
| CA2721052C (en) | 2008-04-11 | 2023-02-21 | Chugai Seiyaku Kabushiki Kaisha | Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly |
| ES2564635T3 (es) | 2008-05-13 | 2016-03-28 | Novimmune Sa | Anticuerpos anti-IL-6/IL-6R y métodos de uso de los mismos |
| EP2669298A3 (en) * | 2008-05-23 | 2014-02-26 | Ablexis, LLC | Single variable immunoglobulin domain comprising VL-DH-JL |
| CA2728243C (en) | 2008-06-05 | 2020-03-10 | National Cancer Center | Il-6 inhibitor for suppressing neuroinvasion in pancreatic cancer |
| ES2445193T3 (es) | 2008-06-27 | 2014-02-28 | Merus B.V. | Mamíferos no humanos productores de anticuerpos |
| TWI440469B (zh) * | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| AU2012200724B8 (en) * | 2008-09-26 | 2014-09-11 | Chugai Seiyaku Kabushiki Kaisha | Improved antibody molecules |
| RU2532826C2 (ru) | 2008-11-13 | 2014-11-10 | Фемта Фармасьютикалз, Инк. | Гуманизированные антитела против il-6 |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| US9212223B2 (en) | 2008-11-25 | 2015-12-15 | Alderbio Holdings Llc | Antagonists of IL-6 to prevent or treat thrombosis |
| US8323649B2 (en) | 2008-11-25 | 2012-12-04 | Alderbio Holdings Llc | Antibodies to IL-6 and use thereof |
| US8420089B2 (en) | 2008-11-25 | 2013-04-16 | Alderbio Holdings Llc | Antagonists of IL-6 to raise albumin and/or lower CRP |
| US8337847B2 (en) | 2008-11-25 | 2012-12-25 | Alderbio Holdings Llc | Methods of treating anemia using anti-IL-6 antibodies |
| US9452227B2 (en) | 2008-11-25 | 2016-09-27 | Alderbio Holdings Llc | Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments |
| JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
| CA2744103C (en) * | 2009-02-24 | 2018-01-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Methods for identifying immunobinders of cell-surface antigens |
| RU2577965C2 (ru) * | 2009-02-24 | 2016-03-20 | ИЭсБиЭйТЕК, ЭН АЛЬКОН БАЙОМЕДИКАЛ РИСЕРЧ ЮНИТ ЭлЭлСи | Способ идентификации иммунных связывающих веществ поверхностных антигенов клетки |
| WO2010107109A1 (ja) | 2009-03-19 | 2010-09-23 | 中外製薬株式会社 | 抗体定常領域改変体 |
| TWI440470B (zh) * | 2009-03-19 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | 含改良抗體分子之醫藥配方 |
| US9228017B2 (en) | 2009-03-19 | 2016-01-05 | Chugai Seiyaku Kabushiki Kaisha | Antibody constant region variant |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| MX2011010681A (es) | 2009-04-10 | 2012-01-20 | Ablynx Nv | Secuencias mejoradas de aminoacidos dirigidas contra il-6r y polipeptidos que comprenden el mismo para el tratamiento de enfermedades y trastornos relacionados con il-6r. |
| EP2417162A2 (en) * | 2009-04-10 | 2012-02-15 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders |
| ES2948572T3 (es) | 2009-07-08 | 2023-09-14 | Kymab Ltd | Modelos de roedores y moléculas terapéuticas |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| DK2493922T3 (en) | 2009-10-26 | 2017-04-24 | Hoffmann La Roche | Process for preparing a glycosylated immunoglobulin |
| EP2504030A4 (en) | 2009-11-24 | 2013-06-26 | Alderbio Holdings Llc | IL-6 ANTAGONISTS FOR INCREASING ALBUMIN AND / OR REDUCING CRP |
| US9775921B2 (en) | 2009-11-24 | 2017-10-03 | Alderbio Holdings Llc | Subcutaneously administrable composition containing anti-IL-6 antibody |
| MY172472A (en) | 2009-12-10 | 2019-11-26 | Regeneron Pharma | Mice that make heavy chain antibodies |
| JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| JO3183B1 (ar) | 2010-01-29 | 2018-03-08 | Regeneron Pharma | طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| ES2547142T5 (es) | 2010-02-08 | 2021-12-09 | Regeneron Pharma | Cadena ligera común de ratón |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| US9273316B2 (en) * | 2010-05-21 | 2016-03-01 | Peptimed, Inc. | Reagents and methods for treating cancer |
| JO3340B1 (ar) | 2010-05-26 | 2019-03-13 | Regeneron Pharma | مضادات حيوية لـعامل تمايز النمو 8 البشري |
| SI2578231T1 (sl) | 2010-05-28 | 2023-01-31 | Chugai Seiyaku Kabushiki Kaisha | Okrepljen protitumorski T celični odzivnik |
| KR101900435B1 (ko) * | 2010-06-16 | 2018-09-20 | 트렐리스 바이오싸이언스 인코포레이티드 | 인간 사이토메갈로바이러스 gB 단백질에 대한 고친화도 인간 항체 |
| IL315833A (en) | 2010-08-02 | 2024-11-01 | Regeneron Pharma | Mice producing binding proteins containing VL regions |
| AR083044A1 (es) * | 2010-09-27 | 2013-01-30 | Regeneron Pharma | Anticuerpos anti-cd48 y usos de los mismos |
| US9533039B2 (en) | 2010-09-27 | 2017-01-03 | Regeneron Pharmaceuticals, Inc. | Methods of treating systemic lupus erythematosus (SLE) using anti-CD48 antibodies |
| JO3375B1 (ar) | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| EP2643018B1 (en) | 2010-11-23 | 2020-10-14 | AlderBio Holdings LLC | Anti-il-6 antibodies for the treatment of oral mucositis |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| BR112013013354A2 (pt) | 2010-11-30 | 2020-10-06 | Chugai Seiyaku Kabushiki Kaisha | molécula de ligação ao antígeno capaz de se ligar a uma pluralidade de moléculas de antígeno repetidamente |
| US20120189621A1 (en) | 2011-01-21 | 2012-07-26 | Yann Dean | Combination Therapies and Methods Using Anti-CD3 Modulating Agents and Anti-IL-6 Antagonists |
| MX347602B (es) | 2011-01-28 | 2017-05-03 | Sanofi Biotechnology | Composiciones farmaceuticas que comprenden anticuerpos humanos frente a pcsk9. |
| HUE024534T2 (hu) | 2011-02-25 | 2016-01-28 | Regeneron Pharma | ADAM6 egerek |
| RU2013144392A (ru) * | 2011-03-03 | 2015-04-10 | Апексиджен, Инк. | Антитела к рецептору il-6 и способы применения |
| EP2695947B1 (en) * | 2011-04-01 | 2017-03-01 | Chugai Seiyaku Kabushiki Kaisha | Recombinant polypeptide production method |
| DK2527842T3 (da) | 2011-05-12 | 2013-09-08 | Regeneron Pharma | Neuropeptidfrisætningsanalyse til natriumkanaler |
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| IL273982B2 (en) | 2011-08-05 | 2023-03-01 | Regeneron Pharma | Humanized mice possess a universal light chain |
| EP2757875B2 (en) | 2011-09-19 | 2023-03-22 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| DK2747782T3 (en) | 2011-09-23 | 2018-04-23 | Ablynx Nv | Long-term inhibition of interleukin-6-mediated signal transmission |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| MX357391B (es) | 2011-09-30 | 2018-07-06 | Regeneron Pharma | Anticuerpos anti-erbb3 y usos de los mismos. |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
| US10246509B2 (en) | 2011-10-17 | 2019-04-02 | Regeneron Pharmaceuticals, Inc. | Restricted immunoglobulin heavy chain mice |
| WO2013059548A1 (en) | 2011-10-19 | 2013-04-25 | Sanofi | Compositions and methods for treating cancer using jak2 inhibitor |
| CN103059137A (zh) * | 2011-10-21 | 2013-04-24 | 神州细胞工程有限公司 | 抗hIL6R高亲和力抗体的制备及应用 |
| WO2013059426A1 (en) * | 2011-10-21 | 2013-04-25 | The Regents Of The University Of California | Human endogenous retrovirus peptides, antibodies to the peptides, and methods of use thereof |
| PL2663575T3 (pl) | 2011-10-28 | 2015-03-31 | Regeneron Pharma | Humanizowane IL-6 i receptor IL-6 |
| JO3370B1 (ar) * | 2011-11-10 | 2019-03-13 | Regeneron Pharma | طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6 |
| SI2780368T1 (en) | 2011-11-14 | 2018-04-30 | Regeneron Pharmaceuticals, Inc. | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A |
| RS60782B1 (sr) | 2011-11-23 | 2020-10-30 | In3Bio Ltd | Rekombinantni proteini i njihove terapeutske upotrebe |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| SG11201403326VA (en) | 2011-12-20 | 2014-07-30 | Regeneron Pharma | Humanized light chain mice |
| US9371383B2 (en) | 2012-01-31 | 2016-06-21 | Regeneron Pharmaceuticals, Inc. | Anti-ASIC1 antibodies and uses thereof |
| IN2014CN04645A (me) | 2012-01-31 | 2015-09-18 | Regeneron Pharma | |
| TWI613215B (zh) | 2012-02-22 | 2018-02-01 | 再生元醫藥公司 | 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途 |
| WO2013130981A1 (en) | 2012-03-02 | 2013-09-06 | Regeneron Pharmaceuticals, Inc. | Human antibodies to clostridium difficile toxins |
| EP3165086A1 (en) | 2012-03-06 | 2017-05-10 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| AU2013204581B2 (en) | 2012-03-16 | 2015-06-25 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing pH-sensitive immunoglobulin sequences |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| EP2825036B1 (en) | 2012-03-16 | 2018-05-02 | Regeneron Pharmaceuticals, Inc. | Histidine engineered light chain antibodies and genetically modified rodents for generating the same |
| RU2664473C2 (ru) | 2012-03-16 | 2018-08-17 | Регенерон Фармасьютикалз, Инк. | ОТЛИЧНЫЕ ОТ ЧЕЛОВЕКА ЖИВОТНЫЕ, ЭКСПРЕССИРУЮЩИЕ ЧУВСТВИТЕЛЬНЫЕ К pН ПОСЛЕДОВАТЕЛЬНОСТИ ИММУНОГЛОБУЛИНОВ |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| TWI619729B (zh) | 2012-04-02 | 2018-04-01 | 再生元醫藥公司 | 抗－ｈｌａ－ｂ*２７抗體及其用途 |
| CN120383672A (zh) | 2012-04-20 | 2025-07-29 | 美勒斯公司 | 用于产生免疫球蛋白样分子的方法和手段 |
| JO3820B1 (ar) | 2012-05-03 | 2021-01-31 | Regeneron Pharma | أجسام مضادة بشرية لـ fel d1وطرق لاستخدامها |
| PT3597037T (pt) | 2012-06-12 | 2021-06-01 | Regeneron Pharma | Animais não humanos humanizados com lócus de cadeia pesada de imunoglobulina restrito |
| TWI641619B (zh) | 2012-06-25 | 2018-11-21 | 美商再生元醫藥公司 | 抗－ｅｇｆｒ抗體及其用途 |
| RU2690675C2 (ru) | 2012-08-21 | 2019-06-05 | Санофи Байотекнолоджи | Способы лечения или предотвращения астмы посредством введения антагониста il-4r |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| ES2981062T3 (es) | 2012-09-07 | 2024-10-07 | Regeneron Pharma | Métodos para el tratamiento de la dermatitis atópica administrando un antagonista de IL-4R |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JP2016502520A (ja) | 2012-11-13 | 2016-01-28 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 抗プロキネチシン受容体（ｐｒｏｋｒ）抗体およびその使用 |
| JO3405B1 (ar) | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| SMT201800435T1 (it) | 2013-02-20 | 2018-09-13 | Regeneron Pharma | Animali non umani con sequenze della catena pesante dell’immunoglobulina modificate riferimento incrociato a domande correlate |
| CN105189545A (zh) | 2013-03-13 | 2015-12-23 | 瑞泽恩制药公司 | 常见轻链小鼠 |
| JO3532B1 (ar) | 2013-03-13 | 2020-07-05 | Regeneron Pharma | الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها |
| AU2014244020B2 (en) | 2013-03-13 | 2020-06-04 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| EP2970448B1 (en) | 2013-03-14 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Human antibodies to grem 1 |
| CA2902572A1 (en) | 2013-03-14 | 2014-10-02 | Regeneron Pharmaceuticals, Inc. | Human antibodies to nav1.7 |
| AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| JP6442404B2 (ja) | 2013-06-11 | 2018-12-19 | 国立研究開発法人国立精神・神経医療研究センター | 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法 |
| EP3613432B1 (en) | 2013-06-21 | 2025-08-06 | Sanofi Biotechnology | Methods for treating nasal polyposis by administering an il-4r antagonist |
| TWI655207B (zh) | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| WO2015027154A2 (en) | 2013-08-23 | 2015-02-26 | Regeneron Pharmaceuticals, Inc. | Diagnostic tests and methods for assessing safety, efficacy or outcome of allergen-specific immunotherapy (sit) |
| RU2019121863A (ru) | 2013-09-18 | 2019-08-29 | Регенерон Фармасьютикалз, Инк. | Антитела со встроенным в легкие цепи гистидином и генетически модифицированные отличные от человека животные для их получения |
| GB201316644D0 (en) | 2013-09-19 | 2013-11-06 | Kymab Ltd | Expression vector production & High-Throughput cell screening |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| US10261094B2 (en) | 2013-10-31 | 2019-04-16 | Regeneron Pharmaceuticals, Inc. | Competitive ligand binding assay for detecting neutralizing antibodies |
| MX377716B (es) | 2013-11-20 | 2025-03-11 | Regeneron Pharma | Moduladores de aplnr y usos de estos. |
| US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
| US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
| WO2015095511A2 (en) * | 2013-12-20 | 2015-06-25 | The Scripps Research Institute | Functional antibodies that modulate cell death and related methods |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| TWI680138B (zh) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗ｐｄ-ｌ１之人類抗體 |
| WO2015116852A1 (en) * | 2014-01-29 | 2015-08-06 | Regeneron Pharmaceuticals, Inc. | Methods for treating rheumatoid arthritis by administering an il-6r antibody |
| IL315136A (en) | 2014-02-21 | 2024-10-01 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-4rantagonist |
| KR102399005B1 (ko) | 2014-03-11 | 2022-05-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-egfrviii 항체 및 그것의 용도 |
| TWI754319B (zh) | 2014-03-19 | 2022-02-01 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
| BR112016021572A2 (pt) | 2014-03-21 | 2017-10-03 | Regeneron Pharma | Métodos para preparar um animal não humano geneticamente modificado e para produzir proteínas de ligação, hibridoma, ácido nucleico, célula, e, proteína de ligação |
| ES2762640T3 (es) | 2014-03-21 | 2020-05-25 | Regeneron Pharma | Proteínas VL de unión a antígeno que exhiben diferentes características de unión |
| JO3701B1 (ar) | 2014-05-23 | 2021-01-31 | Regeneron Pharma | مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي |
| CN107001461A (zh) | 2014-09-16 | 2017-08-01 | 瑞泽恩制药公司 | 抗胰高血糖素抗体及其使用方法 |
| MX2017003841A (es) | 2014-09-23 | 2018-02-23 | Regeneron Pharma | Anticuerpos anti-il-25 y usos de los mismos. |
| WO2016062766A1 (en) | 2014-10-21 | 2016-04-28 | Ablynx Nv | Treatment of il-6r related diseases |
| MX2017006286A (es) | 2014-11-14 | 2018-01-23 | Sanofi Biotechnology | Metodos para tratar sinusitis cronica con polipos nasales por administracion de un antagonista de il-4r. |
| EP3699198B1 (en) | 2014-11-17 | 2025-03-26 | Regeneron Pharmaceuticals, Inc. | Methods for tumor treatment using cd3xcd20 bispecific antibody |
| US20160152717A1 (en) * | 2014-12-02 | 2016-06-02 | Regeneron Pharmaceuticals, Inc. | Methods for treating dry eye disease by administering an il-6r antagonist |
| TWI702229B (zh) | 2014-12-19 | 2020-08-21 | 美商再生元醫藥公司 | 流行性感冒病毒血球凝集素之人類抗體 |
| TWI710573B (zh) | 2015-01-26 | 2020-11-21 | 美商再生元醫藥公司 | 抗伊波拉病毒醣蛋白之人類抗體 |
| RU2730590C2 (ru) | 2015-02-27 | 2020-08-24 | Чугаи Сейяку Кабусики Кайся | Композиция для лечения заболеваний, связанных с ил-6 |
| EP3271403A1 (en) | 2015-03-19 | 2018-01-24 | Regeneron Pharmaceuticals, Inc. | Non-human animals that select for light chain variable regions that bind antigen |
| WO2016159213A1 (ja) | 2015-04-01 | 2016-10-06 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
| IL255010B2 (en) | 2015-04-15 | 2024-01-01 | Regeneron Pharma | Methods of increasing strength and functionality with gdf8 inhibitors |
| JP2016208934A (ja) * | 2015-05-12 | 2016-12-15 | 学校法人日本大学 | 抗イヌインターロイキン−６受容体モノクローナル抗体又は抗体フラグメント及びその利用 |
| ES2888801T3 (es) | 2015-05-19 | 2022-01-07 | Nat Center Neurology & Psychiatry | Método para determinar la aplicación de una terapia nueva en pacientes con esclerosis múltiple (EM) |
| US11174317B2 (en) | 2015-06-04 | 2021-11-16 | National Center Of Neurology And Psychiatry | Therapeutic agent for mental illness comprising IL-6 inhibitor as active ingredient |
| CA2987641A1 (en) | 2015-07-06 | 2017-01-12 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules and uses thereof |
| JOP20160154B1 (ar) | 2015-07-31 | 2021-08-17 | Regeneron Pharma | أجسام ضادة مضاد لل psma، وجزيئات رابطة لمستضد ثنائي النوعية الذي يربط psma و cd3، واستخداماتها |
| TW202440903A (zh) | 2015-08-04 | 2024-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法（一） |
| US10772956B2 (en) | 2015-08-18 | 2020-09-15 | Regeneron Pharmaceuticals, Inc. | Methods for reducing or eliminating the need for lipoprotein apheresis in patients with hyperlipidemia by administering alirocumab |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| HRP20231156T1 (hr) | 2015-12-22 | 2024-01-05 | Regeneron Pharmaceuticals, Inc. | Kombinacija anti-pd-1 antitijela i bispecifičnih anti-cd20/anti-cd3 antitijela za liječenje raka |
| CA3004288C (en) | 2015-12-28 | 2025-05-27 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR PROMOTING THE CLEARANCE EFFICIENCY OF A POLYPEPTIDE CONTAINING THE FC REGION |
| IL302725A (en) | 2016-01-13 | 2023-07-01 | Regeneron Pharma | Rodents having an engineered heavy chain diversity region |
| SG11201806427WA (en) | 2016-02-16 | 2018-08-30 | Regeneron Pharma | Non-human animals having a mutant kynureninase gene |
| EP3216461A1 (en) | 2016-03-07 | 2017-09-13 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| SG10202012182YA (en) | 2016-03-07 | 2021-01-28 | Sanofi Biotechnology | Compositions and methods for treating rheumatoid arthritis |
| AU2017248356A1 (en) | 2016-04-08 | 2018-10-25 | Regeneron Pharmaceuticals, Inc. | Methods for treating hyperlipidemia with an ANGPTL8 inhibitor and an ANGPTL3 inhibitor |
| TW201803981A (zh) * | 2016-04-20 | 2018-02-01 | 再生元醫藥公司 | 用於以使用增強表現基因座爲基礎製造抗體之組成物及方法 |
| SG10202010155YA (en) * | 2016-04-20 | 2020-11-27 | Regeneron Pharma | Compositions and methods for making antibodies based on use of expression-enhancing loci |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| TWI755395B (zh) | 2016-05-13 | 2022-02-21 | 美商再生元醫藥公司 | 抗-pd-1抗體與輻射治療癌症之組合 |
| MX2018014172A (es) | 2016-05-20 | 2019-08-22 | Regeneron Pharma | Métodos para romper la tolerancia inmunológica usando múltiples arn guías. |
| WO2017201731A1 (en) | 2016-05-27 | 2017-11-30 | Beijing Vdjbio Co., Ltd. | Antibodies, composition and kits comprising same, and methods of use thereof |
| WO2017214089A1 (en) | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| MY200162A (en) | 2016-06-10 | 2023-12-09 | Regeneron Pharma | Anti-gitr antibodies and uses thereof |
| MY196006A (en) | 2016-06-14 | 2023-03-06 | Regeneron Pharma | Anti-C5 Antibodies and Uses Thereof |
| TW201815821A (zh) | 2016-07-18 | 2018-05-01 | 美商再生元醫藥公司 | 抗茲卡病毒抗體及使用方法 |
| RU2656160C2 (ru) * | 2016-08-17 | 2018-05-31 | Закрытое Акционерное Общество "Биокад" | Антитело или его антигенсвязывающий фрагмент, способный связываться с рецептором интерлейкина-6 человека |
| EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
| EP4442323A3 (en) | 2016-09-01 | 2025-01-01 | Regeneron Pharmaceuticals, Inc. | Methods for preventing or treating allergy by administering an il-4r antagonist |
| MA46417A (fr) | 2016-09-23 | 2019-07-31 | Regeneron Pharma | Anticorps anti-steap2, conjugués anticorps-médicament, et molécules bispécifiques de liaison à l'antigène qui se lient à steap2 et cd3, et leurs utilisations |
| RS63660B1 (sr) | 2016-09-23 | 2022-11-30 | Regeneron Pharma | Anti-muc16 (mucin 16) antitela |
| CA3038720A1 (en) | 2016-11-04 | 2018-07-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| JP7133551B2 (ja) | 2016-11-17 | 2022-09-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ａｎｇｐｔｌ８抗体を用いて肥満を処置する方法 |
| KR20190091290A (ko) | 2016-11-29 | 2019-08-05 | 리제너론 파아마슈티컬스, 인크. | Ｐｒｌｒ 양성 유방암 치료 방법 |
| MY200701A (en) | 2016-11-29 | 2024-01-11 | Regeneron Pharma | Method of averting opioid addiction |
| BR112019011186A2 (pt) | 2016-12-01 | 2019-10-08 | Regeneron Pharmaceuticals, Inc. | conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor. |
| TWI784988B (zh) | 2016-12-01 | 2022-12-01 | 美商再生元醫藥公司 | 治療發炎症狀的方法 |
| WO2018118713A1 (en) | 2016-12-22 | 2018-06-28 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| CN110650974B (zh) | 2017-02-10 | 2024-04-19 | 瑞泽恩制药公司 | 用于免疫-pet成像的放射性标记的抗-lag3抗体 |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| JP7185884B2 (ja) | 2017-05-02 | 2022-12-08 | 国立研究開発法人国立精神・神経医療研究センター | Ｉｌ－６及び好中球の関連する疾患の治療効果の予測及び判定方法 |
| IL298034B2 (en) | 2017-06-01 | 2024-05-01 | Regeneron Pharma | Antibodies against BET V 1 and methods of using them |
| BR112019025888A2 (pt) | 2017-06-07 | 2020-06-30 | Regeneron Pharmaceuticals, Inc. | polinucleotídeo que codifica uma proteína terapêutica multidomínio, vetor de terapia gênica, proteína terapêutica multidomínio recombinante, método de expressão, métodos para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade, para reduzir o acúmulo de glicogênio em um tecido em um paciente em necessidade epara tratar a deficiência enzimática em um paciente em necessidade e/ou tolerar o paciente à enzima para a qual é deficiente, anticorpo anti-cd63 ou fragmento de ligação a antígeno, e, composição farmacêutica |
| WO2018234879A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| WO2018235056A1 (en) | 2017-06-22 | 2018-12-27 | Novartis Ag | Il-1beta binding antibodies for use in treating cancer |
| US10806780B2 (en) | 2017-06-28 | 2020-10-20 | Regeneron Pharmaceuticals, Inc. | Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof |
| EP3967765A1 (en) | 2017-07-06 | 2022-03-16 | FrieslandCampina Nederland B.V. | Cell culture process for making a glycoprotein |
| TWI799432B (zh) | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | 抗ctla-4抗體及其用途 |
| CN111051343B (zh) * | 2017-09-13 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | Il-6r抗体、其抗原结合片段及医药用途 |
| CN111148758B (zh) | 2017-09-29 | 2022-12-09 | 瑞泽恩制药公司 | 结合葡萄球菌属靶抗原和补体成分的双特异性抗原结合分子及其用途 |
| WO2019078344A1 (ja) | 2017-10-20 | 2019-04-25 | 学校法人兵庫医科大学 | 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物 |
| KR20250044796A (ko) | 2017-10-30 | 2025-04-01 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법 |
| US11066474B2 (en) | 2017-11-30 | 2021-07-20 | Regeneron Pharmaceuticals, Inc. | Anti-TrkB monoclonal antibodies and methods of use |
| SG11202003044SA (en) | 2017-12-05 | 2020-04-29 | Regeneron Pharma | Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof |
| KR20200098528A (ko) | 2017-12-13 | 2020-08-20 | 리제너론 파아마슈티컬스, 인크. | 항-c5 항체 조합물 및 이의 용도 |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| US11977081B2 (en) | 2017-12-18 | 2024-05-07 | Regeneron Pharmaceuticals, Inc. | ANGPTL8 assay and uses thereof |
| WO2019126123A1 (en) | 2017-12-22 | 2019-06-27 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing drug product impurities |
| CA3088194A1 (en) | 2018-01-26 | 2019-08-01 | Regeneron Pharmaceuticals, Inc. | Human antibodies to influenza hemagglutinin |
| AU2019215363A1 (en) | 2018-01-31 | 2020-07-23 | Regeneron Pharmaceuticals, Inc. | System and method for characterizing size and charge variant drug product impurities |
| TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
| JP7779653B2 (ja) | 2018-02-07 | 2025-12-03 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療用タンパク質送達のための方法および組成物 |
| KR20200127979A (ko) | 2018-02-28 | 2020-11-11 | 리제너론 파마슈티칼스 인코포레이티드 | 바이러스 오염물질을 확인하기 위한 시스템 및 방법 |
| AU2019226551B2 (en) | 2018-03-01 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | Methods for altering body composition |
| US12259355B2 (en) | 2018-03-19 | 2025-03-25 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| US12253490B2 (en) | 2018-03-19 | 2025-03-18 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| EP4317959A3 (en) | 2018-03-19 | 2024-03-27 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
| CA3094981A1 (en) | 2018-03-26 | 2019-10-03 | Regeneron Pharmaceuticals, Inc. | Anti-pfrh5 antibodies and antigen-binding fragments thereof |
| EP3788075A1 (en) | 2018-04-30 | 2021-03-10 | Regeneron Pharmaceuticals, Inc. | Antibodies, and bispecific antigen-binding molecules that bind her2 and/or aplp2, conjugates, and uses thereof |
| AU2019265703A1 (en) | 2018-05-09 | 2020-11-19 | Regeneron Pharmaceuticals, Inc. | Anti-MSR1 antibodies and methods of use thereof |
| TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
| MY206284A (en) | 2018-05-17 | 2024-12-06 | Regeneron Pharma | Anti-cd63 antibodies, conjugates, and uses thereof |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| MA52966A (fr) | 2018-06-19 | 2021-04-28 | Regeneron Pharma | Anticorps anti-facteur xii/xiia et leurs utilisations |
| SG11202012729YA (en) | 2018-06-21 | 2021-01-28 | Regeneron Pharma | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
| WO2020018825A1 (en) | 2018-07-19 | 2020-01-23 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with bcma specificity and uses thereof |
| TWI838389B (zh) | 2018-07-19 | 2024-04-11 | 美商再生元醫藥公司 | 雙特異性抗-BCMAｘ抗-CD3抗體及其用途 |
| JP7460598B2 (ja) | 2018-08-10 | 2024-04-02 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 膝および／または股関節痛の安全で効果的な処置用の医薬組成物 |
| SG11202101608XA (en) | 2018-08-23 | 2021-03-30 | Regeneron Pharma | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| MY204234A (en) | 2018-08-27 | 2024-08-16 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
| TWI868074B (zh) | 2018-08-29 | 2025-01-01 | 美商再生元醫藥公司 | 用來治療患有類風濕性關節炎之個體的方法及組成物 |
| BR112020026348A2 (pt) | 2018-08-30 | 2021-03-30 | Regeneron Pharmaceuticals, Inc. | Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica |
| SG11202101037QA (en) | 2018-10-23 | 2021-02-25 | Regeneron Pharma | Anti-npr1 antibodies and uses thereof |
| EP3876989A4 (en) | 2018-11-09 | 2022-12-07 | University of Massachusetts | Anti-cfae antibodies and methods of use |
| CN112867732A (zh) | 2018-11-21 | 2021-05-28 | 瑞泽恩制药公司 | 抗葡萄球菌抗体和其用途 |
| MA54540A (fr) | 2018-12-19 | 2021-10-27 | Regeneron Pharma | Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations |
| BR112021010457A2 (pt) | 2018-12-19 | 2021-08-24 | Regeneron Pharmaceuticals, Inc. | Anticorpos biespecíficos anti-muc16 x anti cd28 e usos dos mesmos |
| US20220025036A1 (en) | 2018-12-21 | 2022-01-27 | Novartis Ag | Use of il-1beta binding antibodies |
| AU2020205951A1 (en) * | 2019-01-07 | 2021-07-22 | Hunan Siweikang Therapeutics Co. Ltd | Modified immune cells co-expressing chimeric antigen receptor and il-6 antagonist for reducing toxicity and uses thereof in adoptive cell therapy |
| KR20210114927A (ko) | 2019-01-16 | 2021-09-24 | 리제너론 파마슈티칼스 인코포레이티드 | 이황화 결합을 특징 짓는 방법 |
| EP3917618A1 (en) | 2019-01-31 | 2021-12-08 | Sanofi Biotechnology | Anti-il-6 receptor antibody for treating juvenile idiopathic arthritis |
| EP3923978A1 (en) | 2019-02-12 | 2021-12-22 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for using bispecific antibodies to bind complement and a target antigen |
| JP2022523360A (ja) | 2019-02-21 | 2022-04-22 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｍｅｔに結合する抗ｍｅｔ抗体および二特異性抗原結合分子を使用した眼癌の治療方法 |
| WO2020178193A1 (en) | 2019-03-01 | 2020-09-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method of treatment of sarcoidosis |
| PH12021552123A1 (en) | 2019-03-21 | 2022-08-22 | Regeneron Pharma | Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy |
| US11912767B2 (en) | 2019-03-22 | 2024-02-27 | Regeneron Pharmaceuticals, Inc. | EGFR × CD28 multispecific antibodies |
| MX2021012335A (es) | 2019-04-10 | 2021-11-12 | Regeneron Pharma | Anticuerpos humanos que se unen a ret y metodos de uso de los mismos. |
| JP2022545312A (ja) | 2019-04-24 | 2022-10-27 | サノフィ・バイオテクノロジー | 関節リウマチの診断及び処置の方法 |
| EP3962515A1 (en) | 2019-05-01 | 2022-03-09 | Sanofi Biotechnology | Methods for treating or preventing asthma by administering an il-33 antagonist |
| MX2021013519A (es) | 2019-05-13 | 2021-12-10 | Regeneron Pharma | Ensayos de union de ligandos competitivos mejorados. |
| MA56116A (fr) | 2019-06-04 | 2022-04-13 | Stefano Fiore | Compositions et procédés de traitement de la douleur chez des sujets atteints de polyarthrite rhumatoïde |
| SG11202111258TA (en) | 2019-06-05 | 2021-11-29 | Regeneron Pharma | Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof |
| AU2020292283A1 (en) | 2019-06-11 | 2021-12-23 | Regeneron Pharmaceuticals, Inc. | Anti-PcrV antibodies that bind PcrV, compositions comprising anti-PcrV antibodies, and methods of use thereof |
| AU2020290971A1 (en) * | 2019-06-14 | 2021-12-23 | Dana-Farber Cancer Institute, Inc. | Antibodies against PD-1 and methods of use thereof |
| US20220249640A1 (en) * | 2019-06-14 | 2022-08-11 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| EP3986481A2 (en) | 2019-06-20 | 2022-04-27 | Takeda Pharmaceutical Company Limited | Method of treatment with viral-based gene therapy |
| JP7592064B2 (ja) | 2019-07-16 | 2024-11-29 | サノフィ・バイオテクノロジー | Ｉｌ－４ｒアンタゴニストを投与することにより喘息を治療するまたは予防するための方法 |
| BR112022001194A2 (pt) | 2019-07-24 | 2022-06-07 | Regeneron Pharma | Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos |
| CN114340684B (zh) | 2019-09-16 | 2025-09-12 | 瑞泽恩制药公司 | 用于免疫pet成像的放射性标记的met结合蛋白 |
| CN114667450B (zh) | 2019-09-24 | 2025-05-02 | 里珍纳龙药品有限公司 | 用于色谱介质的使用和再生的系统及方法 |
| US12297451B1 (en) | 2019-10-25 | 2025-05-13 | Regeneron Pharmaceuticals, Inc. | Cell culture medium |
| CN114761428A (zh) | 2019-10-28 | 2022-07-15 | 瑞泽恩制药公司 | 抗血凝素抗体及其使用方法 |
| US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
| MX2022006812A (es) | 2019-12-06 | 2022-08-25 | Sanofi Biotechnology | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |
| MX2022006714A (es) | 2019-12-06 | 2022-08-08 | Regeneron Pharma | Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos. |
| EP4081544A1 (en) | 2019-12-23 | 2022-11-02 | Sanofi Biotechnology | Methods for treating or preventing allergic asthma by administering an il-33 antagonist and/or an il-4r antagonist |
| EP4354145B1 (en) | 2020-01-21 | 2025-09-17 | Regeneron Pharmaceuticals, Inc. | Deglycosylation methods for electrophoresis of glycosylated proteins |
| US20230390391A1 (en) | 2020-01-22 | 2023-12-07 | Regents Of The University Of Minnesota | Bi-specific chimeric antigen receptor t cells targeting cd83 and interleukin 6 receptor |
| JP7772702B2 (ja) | 2020-02-10 | 2025-11-18 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｔｍｐｒｓｓ２抗体および抗原結合断片 |
| AU2021218675A1 (en) | 2020-02-11 | 2022-08-18 | Regeneron Pharmaceuticals, Inc. | Anti-ACVR1 antibodies and uses thereof |
| MX2022010599A (es) | 2020-02-28 | 2022-09-09 | Regeneron Pharma | Moleculas biespecificas de union al antigeno que se unen a her2, y metodos de uso de los mismos. |
| PH12022552295A1 (en) | 2020-03-06 | 2024-01-22 | Regeneron Pharma | Anti-gitr antibodies and uses thereof |
| WO2021045836A1 (en) | 2020-04-02 | 2021-03-11 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| EP4146692A1 (en) * | 2020-05-06 | 2023-03-15 | Sorrento Therapeutics, Inc. | Neutralizing antibodies that bind the sars-cov-2 s protein |
| BR112022022941A2 (pt) | 2020-05-12 | 2023-01-10 | Regeneron Pharma | Anticorpos antagonistas anti-glp1r e métodos de uso dos mesmos |
| KR20230009502A (ko) * | 2020-05-18 | 2023-01-17 | 바이오션, 인코포레이티드 | Il6r에 결합하는 항체 및 이의 용도 |
| CN116096745A (zh) | 2020-05-26 | 2023-05-09 | 瑞泽恩制药公司 | 抗sars-cov-2纤突糖蛋白抗体和抗原结合片段 |
| CA3180369A1 (en) | 2020-05-26 | 2021-12-02 | Inka Albrecht | Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same |
| JP2023527200A (ja) | 2020-05-29 | 2023-06-27 | サノフィ・バイオテクノロジー | 関節リウマチを有する対象における非炎症性疼痛を治療するための組成物および方法 |
| WO2021257695A2 (en) * | 2020-06-16 | 2021-12-23 | Hifibio (Hk) Limited | Methods and compositions related to neutralizing antibodies against human coronavirus |
| US20230416343A1 (en) * | 2020-08-07 | 2023-12-28 | Sorrento Therapeutics, Inc. | Neutralizing Antibodies that Bind the SARS-COV-2 S Protein |
| EP4200017A1 (en) | 2020-08-20 | 2023-06-28 | Regeneron Pharmaceuticals, Inc. | Methods for preventing and treating cardiac dysfunction and covid-19 with activin a antagonists |
| EP4204449A1 (en) | 2020-08-26 | 2023-07-05 | Regeneron Pharmaceuticals, Inc. | Method of treating an allergy with allergen-specific monoclonal antibodies |
| CA3192999A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
| TW202229328A (zh) | 2020-09-11 | 2022-08-01 | 美商再生元醫藥公司 | 抗原特異性抗體之鑑定及產生 |
| JP2023543152A (ja) | 2020-09-18 | 2023-10-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｃｄ３８及び／又はｃｄ２８を結合する抗原結合分子及びその使用 |
| AU2021357078A1 (en) | 2020-10-05 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating asthma in pediatric subjects by administering an il-4r antagonist |
| IL301702A (en) | 2020-10-22 | 2023-05-01 | Regeneron Pharma | Anti-FGFR2 antibodies and methods of using them |
| KR20230113280A (ko) | 2020-11-25 | 2023-07-28 | 리제너론 파마슈티칼스 인코포레이티드 | 비수성 멤브레인 유화법을 사용한 지속 방출 제형 |
| CN116710124A (zh) | 2020-12-17 | 2023-09-05 | 瑞泽恩制药公司 | 包封蛋白质的微凝胶的制造 |
| CA3202629A1 (en) | 2020-12-18 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Immunoglobulin proteins that bind to npr1 agonists |
| IL303868A (en) | 2020-12-23 | 2023-08-01 | Regeneron Pharma | Nucleic acids encoding anchor-modified antibodies and uses thereof |
| US12031151B2 (en) | 2021-01-20 | 2024-07-09 | Regeneron Pharmaceuticals, Inc. | Methods of improving protein titer in cell culture |
| AR125585A1 (es) | 2021-03-03 | 2023-08-02 | Regeneron Pharma | Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas |
| WO2022187626A1 (en) | 2021-03-05 | 2022-09-09 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-variant-spike glycoprotein antibodies and antigen-binding fragments |
| MX2023010794A (es) | 2021-03-26 | 2023-10-25 | Regeneron Pharma | Metodos y sistemas para el desarrollo de protocolos de mezcla. |
| KR102871709B1 (ko) | 2021-04-20 | 2025-10-17 | 리제너론 파마슈티칼스 인코포레이티드 | 아르테민에 대한 인간 항체 및 이의 사용 방법 |
| KR20240005854A (ko) | 2021-05-04 | 2024-01-12 | 리제너론 파아마슈티컬스, 인크. | Mage-a4 특이성을 갖는 키메라 항원 수용체 및 이들의 용도 |
| MX2023012974A (es) | 2021-05-04 | 2023-11-15 | Regeneron Pharma | Agonistas multiespecificos de receptores del fgf21 y sus usos. |
| AU2022274888A1 (en) | 2021-05-11 | 2023-12-07 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| EP4347651A1 (en) | 2021-06-01 | 2024-04-10 | Les Laboratoires Servier | Anti-nkg2a antibodies and compositions |
| CA3220848A1 (en) | 2021-06-01 | 2022-12-08 | Timothy Riehlman | Microchip capillary electrophoresis assays and reagents |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| US20240316169A1 (en) | 2021-07-05 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Utilization of antibodies to shape antibody responses to an antigen |
| AU2022311906A1 (en) | 2021-07-14 | 2024-01-25 | Regeneron Pharmaceuticals, Inc. | Anti-sars-cov-2-spike glycoprotein antibodies and antigen-binding fragments |
| MX2024001189A (es) | 2021-07-26 | 2024-02-27 | Sanofi Biotechnology | Metodos para tratar la urticaria cronica espontanea por administracion de un antagonista de il-4r. |
| TW202326138A (zh) | 2021-09-08 | 2023-07-01 | 美商再生元醫藥公司 | 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法 |
| JP2024531800A (ja) | 2021-09-20 | 2024-08-29 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗体の不均一性を制御する方法 |
| TW202323817A (zh) | 2021-10-07 | 2023-06-16 | 美商再生元醫藥公司 | Ｐｈ建模及控制之系統及方法 |
| KR20240090312A (ko) | 2021-10-07 | 2024-06-21 | 리제너론 파아마슈티컬스, 인크. | Ph 미터 보정 및 교정 |
| KR20240099290A (ko) | 2021-10-20 | 2024-06-28 | 사노피 바이오테크놀로지 | Il-4r 길항제를 투여하여 결절성 양진을 치료하는 방법 |
| CA3235457A1 (en) | 2021-10-22 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Factor xi a2 domain-binding antibodies and methods of use thereof |
| CA3236367A1 (en) | 2021-10-26 | 2023-05-04 | Michelle Lafond | Systems and methods for generating laboratory water and distributing laboratory water at different temperatures |
| US20250011408A1 (en) | 2021-11-19 | 2025-01-09 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for reducing centralized pain |
| US20230250170A1 (en) | 2021-12-06 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Antagonist anti-npr1 antibodies and methods of use thereof |
| JP2025508233A (ja) | 2022-03-18 | 2025-03-21 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ポリペプチド変異体を分析するための方法およびシステム |
| WO2023196903A1 (en) | 2022-04-06 | 2023-10-12 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind and cd3 and tumor associated antigens (taas) and uses thereof |
| WO2023212586A1 (en) | 2022-04-27 | 2023-11-02 | Regeneron Pharmaceuticals, Inc. | Methods for selecting patients for treatment with an ngf antagonist |
| US20230416396A1 (en) | 2022-05-18 | 2023-12-28 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof |
| EP4554977A1 (en) | 2022-07-12 | 2025-05-21 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
| EP4580659A1 (en) | 2022-08-29 | 2025-07-09 | Sanofi Biotechnology | Methods for treating chronic inducible cold urticaria by administering an il-4r antagonist |
| IL320397A (en) | 2022-11-07 | 2025-06-01 | Regeneron Pharma | Antibodies binding to the catalytic domain of factor XI and methods of using them |
| US20240190978A1 (en) | 2022-11-15 | 2024-06-13 | CSBioAsset LLC | Compositions and methods for immunomodulatory bifunctional fusion molecules |
| WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
| WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| EP4649092A1 (en) | 2023-01-13 | 2025-11-19 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| TW202445126A (zh) | 2023-01-25 | 2024-11-16 | 美商再生元醫藥公司 | 基於質譜法之體內共表現抗體之表徵 |
| US20240245779A1 (en) | 2023-01-25 | 2024-07-25 | Regeneron Pharmaceuticals, Inc. | Methods of modeling liquid protein composition stability |
| TW202445138A (zh) | 2023-02-01 | 2024-11-16 | 美商再生元醫藥公司 | 用於生物巨分子分析之具質譜法的不對稱流場流分離 |
| CN120677178A (zh) | 2023-02-13 | 2025-09-19 | 瑞泽恩制药公司 | 用抗人cacng1抗体治疗肌肉相关病症 |
| WO2024173876A1 (en) | 2023-02-17 | 2024-08-22 | Regeneron Pharmaceuticals, Inc. | Radiolabeled anti-lag3 antibodies for immuno-pet imaging |
| TW202446462A (zh) | 2023-02-22 | 2024-12-01 | 美商再生元醫藥公司 | 系統適用性參數及管柱老化 |
| TW202502819A (zh) | 2023-03-22 | 2025-01-16 | 法商賽諾菲生物技術公司 | 藉由投予il-4r拮抗劑治療慢性阻塞性肺病(copd)之方法 |
| TW202508625A (zh) | 2023-05-01 | 2025-03-01 | 美商再生元醫藥公司 | 使用苯酚或苯甲醇之多劑量抗體藥物產品 |
| CN121039163A (zh) | 2023-05-02 | 2025-11-28 | 瑞泽恩制药公司 | 抗人m-钙粘蛋白（cdh15）抗体、缀合物及其用于将遗传有效负载递送至肌肉细胞的用途 |
| WO2024259206A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharmaceuticals, Inc. | Cd40 x cd40 bispecific antigen-binding molecules and uses thereof |
| WO2025014533A1 (en) | 2023-07-10 | 2025-01-16 | Regeneron Pharmaceuticals, Inc. | Anti-human cacng1 antibody-drug conjugates and uses thereof |
| CN119285767B (zh) * | 2023-07-10 | 2025-11-18 | 东莞市朋志生物科技有限公司 | 抗白介素-6抗体、检测白介素-6的试剂和试剂盒 |
| TW202519559A (zh) | 2023-07-10 | 2025-05-16 | 美商再生元醫藥公司 | 雙特異性PD-L1xCD28抗體及其使用方法 |
| US20250043017A1 (en) | 2023-07-10 | 2025-02-06 | Regeneron Pharmaceuticals, Inc. | BISPECIFIC PD-L1x4-1BB ANTIBODIES AND METHODS OF USE THEREOF |
| WO2025019789A1 (en) | 2023-07-19 | 2025-01-23 | Regeneron Pharmaceuticals, Inc. | ANTI-FACTOR XII/XIIa ANTIBODIES AND USES THEREOF |
| WO2025054406A1 (en) | 2023-09-08 | 2025-03-13 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
| US20250095773A1 (en) | 2023-09-18 | 2025-03-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for developing chromatography protocols |
| WO2025072597A2 (en) | 2023-09-29 | 2025-04-03 | Regeneron Pharmaceuticals, Inc. | Lyophilization using controlled nucleation |
| US20250129117A1 (en) | 2023-10-18 | 2025-04-24 | Regeneron Pharmaceuticals, Inc. | Rapid purification of monoclonal antibody from in-process upstream cell culture material |
| WO2025096932A1 (en) | 2023-11-02 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipase activity using stress |
| WO2025149845A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Treatment of subjects with polymyalgia rheumatica who have been receiving a steroid |
| WO2025149846A1 (en) | 2024-01-12 | 2025-07-17 | Sanofi Biotechnology | Compositions and methods for treating frail subjects with polymyalgia rheumatica by administering an il-6r antagonist |
| WO2025166281A1 (en) | 2024-02-01 | 2025-08-07 | Regeneron Pharmaceuticals, Inc. | Platform for charge-detection mass spectrometry analysis of aavs |
| WO2025175164A1 (en) | 2024-02-16 | 2025-08-21 | Regeneron Pharmaceuticals, Inc. | Methods of producing concentrated formulated drug substances comprising proteins, and concentrated formulated drug substance made by the methods |
| WO2025194043A1 (en) | 2024-03-15 | 2025-09-18 | Regeneron Pharmaceuticals, Inc. | Polysorbate and polyoxyethylene sorbitan as excipients for stable protein formulations |
| WO2025221640A1 (en) | 2024-04-15 | 2025-10-23 | Sanofi Biotechnology | Methods for treating chronic rhinosinusitis without nasal polyps by administering an il-4r antagonist |
| WO2025240335A1 (en) | 2024-05-13 | 2025-11-20 | Regeneron Pharmaceuticals, Inc. | Fgfr3 binding molecules and methods of use thereof |
| WO2025259840A1 (en) | 2024-06-13 | 2025-12-18 | Regeneron Pharmaceuticals, Inc. | Methods and systems for scaled chromatography |
| CN119775414B (zh) * | 2025-03-12 | 2025-06-06 | 武汉伊莱瑞特生物科技股份有限公司 | 抗猴白介素-6单克隆抗体、酶联免疫检测试剂盒及其应用 |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
| US5171840A (en) * | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5216128A (en) | 1989-06-01 | 1993-06-01 | Yeda Research And Development Co., Ltd. | IFN-β2/IL-6 receptor its preparation and pharmaceutical compositions containing it |
| SG42954A1 (en) * | 1989-07-20 | 1997-10-17 | Tadamitsu Kishimoto | Antibody to human interleukin-6 receptor |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| TW205553B (me) | 1991-04-25 | 1993-05-11 | Chugai Pharmaceutical Co Ltd | |
| JPH05227970A (ja) * | 1992-02-19 | 1993-09-07 | Chugai Pharmaceut Co Ltd | ヒトインターロイキン−６受容体に対する再構成ヒト抗体 |
| FR2694767B1 (fr) * | 1992-08-13 | 1994-10-21 | Innotherapie Lab Sa | Anticorps monoclonaux anti-IL6R, et leurs applications. |
| EP0672144A1 (en) | 1992-10-20 | 1995-09-20 | Chiron Corporation | Interleukin-6 receptor antagonists |
| US5888511A (en) * | 1993-02-26 | 1999-03-30 | Advanced Biotherapy Concepts, Inc. | Treatment of autoimmune diseases, including AIDS |
| US5888510A (en) * | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
| WO1995009873A1 (en) * | 1993-10-06 | 1995-04-13 | Board Of Regents, The University Of Texas System | A monoclonal anti-human il-6 receptor antibody |
| CA2201781C (en) | 1994-10-07 | 2010-01-12 | Tadamitsu Kishimoto | Chronic rheumatoid arthritis therapy containing il-6 antagonist as effective component |
| EP1884524A3 (en) * | 1994-10-21 | 2008-06-25 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for treatment of diseases caused by IL-6 production |
| AU704723B2 (en) * | 1994-12-29 | 1999-04-29 | Chugai Seiyaku Kabushiki Kaisha | Antitumor agent effect enhancer containing IL-6 antagonist |
| ES2264135T3 (es) * | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
| US6090382A (en) * | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| US5785965A (en) | 1996-05-15 | 1998-07-28 | The Board Of Trustees Of The Leland Stanford Junior Univ. | VEGF gene transfer into endothelial cells for vascular prosthesis |
| WO1997049428A1 (en) | 1996-06-27 | 1997-12-31 | Chugai Seiyaku Kabushiki Kaisha | Remedies for myeloma to be used together with nitrogen mustard antitumor agents |
| KR20090068385A (ko) | 1997-08-15 | 2009-06-26 | 츄가이 세이야꾸 가부시키가이샤 | 항 인터루킨-6 수용체 항체를 유효성분으로서 함유하는 전신성 홍반성 낭창의 예방 및/또는 치료제 |
| US20020187150A1 (en) * | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
| JP4124573B2 (ja) | 1998-03-17 | 2008-07-23 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する炎症性腸疾患の予防又は治療剤 |
| CA2341239C (en) | 1998-08-24 | 2011-01-04 | Chugai Seiyaku Kabushiki Kaisha | A preventive or therapeutic agent for pancreatitis comprising il-6 antagonist as an active ingredient |
| US6787637B1 (en) | 1999-05-28 | 2004-09-07 | Neuralab Limited | N-Terminal amyloid-β antibodies |
| DK1314437T3 (da) | 2000-08-11 | 2014-07-14 | Chugai Pharmaceutical Co Ltd | Stabiliserede antistofindeholdende præparater |
| AU2002210918B2 (en) | 2000-10-20 | 2006-03-16 | Chugai Seiyaku Kabushiki Kaisha | Degraded agonist antibody |
| EP1334731B1 (en) * | 2000-10-25 | 2008-02-27 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
| JP4889187B2 (ja) * | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Ｉｌ−６アンタゴニストを有効成分として含有する血中ｍｍｐ−３濃度低下剤 |
| US6596541B2 (en) * | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| UA80091C2 (en) * | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
| MXPA04007924A (es) | 2002-02-14 | 2005-05-17 | Chugai Pharmaceutical Co Ltd | Formulaciones en solucion que contienen anticuerpo. |
| US20060078533A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer |
| US20060078532A1 (en) * | 2004-10-12 | 2006-04-13 | Omoigui Osemwota S | Method of prevention and treatment of Atherosclerosis, Peripheral vascular disease, Coronary artery disease, aging and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| US20060275294A1 (en) * | 2002-08-22 | 2006-12-07 | Omoigui Osemwota S | Method of prevention and treatment of aging, age-related disorders and/or age-related manifestations including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimers disease and cancer |
| US20060078531A1 (en) * | 2004-10-12 | 2006-04-13 | Osemwota Sota | Method of prevention and treatment of atherosclerosis, peripheral vascular disease, coronary artery disease, and age-related disorders including osteoporosis, arthritis, type 2 diabetes, dementia and Alzheimer's disease |
| AU2003261787B2 (en) * | 2002-08-30 | 2008-11-06 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Human antihuman interleukin-6 antibody and fragment of the antibody |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
| GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
| EP1673396A1 (en) | 2003-09-22 | 2006-06-28 | BioVation GmbH & Co.KG. | Use of antibodies for reducing the biological effectiveness of il-6 |
| US8617550B2 (en) * | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
| DE602005020743D1 (de) * | 2004-02-11 | 2010-06-02 | Warner Lambert Co | Verfahren zur behandlung von osteoarthritis mit anti-il-6 antikörpern |
| US20070036788A1 (en) * | 2004-09-22 | 2007-02-15 | Ahmed Sheriff | Use of a compound for reducing the biological effectiveness of il-6 |
| EP1810980A1 (en) | 2004-10-28 | 2007-07-25 | Osaka University | Interleukin-6 inhibitors |
| US20060177436A1 (en) * | 2004-12-16 | 2006-08-10 | Genentech, Inc. | Methods for Treating Autoimmune Disorders |
| CN101146554B (zh) * | 2005-01-27 | 2012-10-10 | 加州大学评议会 | 中和肉毒杆菌神经毒素的治疗性单克隆抗体 |
| PL2374818T3 (pl) | 2006-06-02 | 2013-05-31 | Regeneron Pharma | Przeciwciała o wysokim powinowactwie przeciw ludzkiemu receptorowi IL 6 |
| US8080248B2 (en) | 2006-06-02 | 2011-12-20 | Regeneron Pharmaceuticals, Inc. | Method of treating rheumatoid arthritis with an IL-6R antibody |
| AU2007285695B2 (en) | 2006-08-18 | 2012-05-24 | Ablynx N.V. | Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling |
| RU2319351C1 (ru) * | 2006-09-13 | 2008-03-20 | Олег Иванович Квасенков | Способ подготовки к хранению яблок свежих специального назначения |
| EP2081960B1 (en) | 2006-10-27 | 2018-06-27 | Ablynx N.V. | Intranasal delivery of polypeptides and proteins |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| WO2009095489A2 (en) | 2008-02-01 | 2009-08-06 | Ablynx N.V. | Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling |
| WO2009109584A1 (en) | 2008-03-07 | 2009-09-11 | Ferring International Center S. A. | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX |
-
2007
- 2007-06-01 PL PL11171039T patent/PL2374818T3/pl unknown
- 2007-06-01 RS RS20120074A patent/RS52176B/sr unknown
- 2007-06-01 CN CN200780019546XA patent/CN101454345B/zh active Active
- 2007-06-01 SI SI200731155T patent/SI2374818T1/sl unknown
- 2007-06-01 HR HR20120175T patent/HRP20120175T1/hr unknown
- 2007-06-01 MY MYPI20084757A patent/MY147468A/en unknown
- 2007-06-01 RS RS20130051A patent/RS52643B/sr unknown
- 2007-06-01 US US11/809,482 patent/US7582298B2/en active Active
- 2007-06-01 SI SI200730858T patent/SI2041177T1/sl unknown
- 2007-06-01 BR BRPI0712224A patent/BRPI0712224B8/pt active IP Right Grant
- 2007-06-01 AT AT07777380T patent/ATE537190T1/de active
- 2007-06-01 RU RU2008152443/10A patent/RU2433138C2/ru active
- 2007-06-01 ES ES07777380T patent/ES2377579T3/es active Active
- 2007-06-01 NZ NZ587107A patent/NZ587107A/en unknown
- 2007-06-01 AU AU2007254831A patent/AU2007254831B2/en active Active
- 2007-06-01 MX MX2008014804A patent/MX2008014804A/es active IP Right Grant
- 2007-06-01 PL PL07777380T patent/PL2041177T3/pl unknown
- 2007-06-01 ME MEP-2008-853A patent/ME00519B/me unknown
- 2007-06-01 EP EP07777380A patent/EP2041177B1/en active Active
- 2007-06-01 EP EP11171039A patent/EP2374818B1/en active Active
- 2007-06-01 WO PCT/US2007/013062 patent/WO2007143168A2/en not_active Ceased
- 2007-06-01 DK DK07777380.2T patent/DK2041177T3/da active
- 2007-06-01 NZ NZ573557A patent/NZ573557A/en unknown
- 2007-06-01 CA CA2652976A patent/CA2652976C/en active Active
- 2007-06-01 MY MYPI2012001581A patent/MY159787A/en unknown
- 2007-06-01 PT PT07777380T patent/PT2041177E/pt unknown
- 2007-06-01 DK DK11171039.8T patent/DK2374818T3/da active
- 2007-06-01 PT PT111710398T patent/PT2374818E/pt unknown
- 2007-06-01 ES ES11171039T patent/ES2398076T3/es active Active
- 2007-06-01 JP JP2009513324A patent/JP5307708B2/ja active Active
- 2007-06-01 CN CN2012100596311A patent/CN102585002A/zh active Pending
-
2008
- 2008-11-19 IL IL195393A patent/IL195393A/en active IP Right Grant
- 2008-11-26 CR CR10462A patent/CR10462A/es unknown
- 2008-11-28 SV SV2008003113A patent/SV2008003113A/es unknown
- 2008-12-02 GT GT200800272A patent/GT200800272A/es unknown
- 2008-12-02 TN TNP2008000502A patent/TNSN08502A1/en unknown
- 2008-12-05 KR KR1020087029749A patent/KR101464502B1/ko active Active
- 2008-12-18 NO NO20085309A patent/NO340778B1/no active Protection Beyond IP Right Term
-
2009
- 2009-07-13 US US12/501,657 patent/US8043617B2/en active Active
-
2011
- 2011-09-12 US US13/230,081 patent/US8183014B2/en active Active
-
2012
- 2012-03-07 CY CY20121100231T patent/CY1112456T1/el unknown
- 2012-04-18 US US13/450,011 patent/US20130157313A1/en not_active Abandoned
-
2013
- 2013-02-21 CY CY20131100159T patent/CY1113708T1/el unknown
- 2013-03-15 HR HRP20130228TT patent/HRP20130228T1/hr unknown
- 2013-05-15 JP JP2013102655A patent/JP5805703B2/ja active Active
-
2014
- 2014-03-12 US US14/206,259 patent/US20140255995A1/en not_active Abandoned
-
2015
- 2015-09-01 JP JP2015171640A patent/JP6140777B2/ja active Active
-
2016
- 2016-04-22 US US15/136,152 patent/US9884916B2/en active Active
-
2017
- 2017-11-13 CY CY2017039C patent/CY2017039I2/el unknown
- 2017-11-14 NO NO2017060C patent/NO2017060I1/no unknown
- 2017-11-15 NL NL300911C patent/NL300911I2/nl unknown
- 2017-11-22 LU LU00050C patent/LUC00050I2/en unknown
- 2017-11-23 LT LTPA2017038C patent/LTC2041177I2/lt unknown
- 2017-12-01 HU HUS1700050C patent/HUS1700050I1/hu unknown
-
2018
- 2018-08-31 US US16/119,695 patent/US10584173B2/en active Active
-
2020
- 2020-01-28 US US16/774,945 patent/US11370843B2/en active Active
-
2022
- 2022-05-20 US US17/749,728 patent/US20230094591A1/en not_active Abandoned
-
2024
- 2024-11-01 US US18/935,325 patent/US20250206829A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME00519B (me) | Antitijela visokog afiniteta prema humanom il-6 receptoru | |
| ES2881602T3 (es) | Conjugados de anticuerpo-fynómero | |
| JP2022191486A (ja) | ヒト抗ｉｌ－３３中和モノクローナル抗体 | |
| JP6883591B2 (ja) | 抗ヒトインターロイキン−１７ａモノクローナル抗体、その製造方法及び使用 | |
| CA2901462C (en) | Antibodies that bind il-23 | |
| CN102037016B (zh) | 针对粒细胞巨噬细胞集落刺激因子的抗体 | |
| RU2019113790A (ru) | Анти-lag-3 антитела и их композиции | |
| JP2016503412A5 (ja) | Ｉｌ−６アンタゴニストおよびその使用 | |
| US20200277366A1 (en) | MULTI-SPECIFIC ANTIBODY MOLECULES HAVING SPECIFICITY FOR TNF-ALPHA, IL-17A and IL-17F | |
| HRP20150799T1 (hr) | Sastavi i postupci za protutijela protiv komplementnog proteina c5 | |
| JP2011514150A5 (me) | ||
| RU2011120194A (ru) | Человеческие антитела с высокой аффинностью к рецепторам il-4 человека | |
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| HRP20160638T1 (hr) | Antigen vezujući proteini sposobni vezati timusni stromalni limfopoetin | |
| JP2009539349A5 (me) | ||
| RU2011145428A (ru) | АНТИТЕЛА ПРОТИВ TNF-α И ИХ ПРИМЕНЕНИЯ | |
| KR20230004576A (ko) | 항인간 인터루킨-4수용체 α항체의 제조방법과 용도 | |
| EP3215529A1 (en) | Anti-tnf-/anti-il-23 bispecific antibodies | |
| TW201904994A (zh) | 抗干擾素-γ之抗體及其應用 | |
| RU2019123112A (ru) | Анти-il-5 антитела | |
| EP3154564B1 (en) | New polypeptide | |
| JP7184310B2 (ja) | 抗ｉｌ－２５抗体およびその使用 | |
| CN117860786B (zh) | 基因修饰间充质干细胞在多种疾病中的制药用途和诊断用途 | |
| KR102048475B1 (ko) | IL-17A (Interleukin-17A)에 특이적으로 결합하는 항체 및 이의 용도 | |
| RU2841957C1 (ru) | Сконструированные антитела против il-2 |